Harnessing Next Generation LNA Antisense Oligonucleotide (ASOs) Platform, LNAplus™

Time: 4:00 pm
day: Focus Day


  • Exploring rapid generation of high-quality development candidates – six months from idea to candidate
  • Parallel evaluation of efficacy and safety – starting at the in-silico stage
  • Overview of successful partnerships across therapeutic areas
  • Presenting examples from the diversified proprietary pre-clinical pipeline for indications of oncology and inflammatory and fibrotic diseases of the kidney and liver